Palisade Bio Inc

This proposal requests shareholder approval to amend the Company’s Certificate of Incorporation to increase authorized common stock from 300 million to 450 million shares (and total authorized capital from 307 million to 457 million). Management frames the change as a precautionary measure to ensure the Company has ample share capacity to support future equity financings, issuance of equity awards, and potential strategic transactions without the time and expense of seeking shareholder approval for each issuance. The Company discloses that, as of the record date, approximately 167.4 million shares were outstanding and roughly 86.9 million additional shares were issuable via warrants, options, RSUs, inducement plan reserve and other commitments, leaving under 16% of the current authorized common shares unissued. The board also notes that the requested increase would provide flexibility to implement the proposed Incentive Plan and ESPP should those be approved, and to respond to future funding needs or strategic opportunities. Management acknowledges the potential for the authorization to be used defensively but states there are no immediate undisclosed plans to issue the additional shares; nonetheless, increased authorization can dilute existing holders if deployed. The amendment would have standard anti-takeover implications (more authorized shares could be issued to frustrate a change in control), though management disclaims anti-takeover intent and Delaware law provides no appraisal rights. Approval requires a majority of votes cast and, if approved, the Board retains discretion whether to file the Certificate of Amendment and whether to actually issue shares. For an analyst, the proposal reduces governance friction for future capital raises and compensation programs but increases the potential supply overhang that could weigh on share value depending on issuance timing and purposes.

Proposal 4 seeks shareholder approval to replace the Company’s existing 2021 Equity Incentive Plan with an Amended and Restated version that fixes the share pool at 42,257,000 shares and removes the prior annual evergreen automatic increase. Management argues this fixed share reserve will be sufficient to support anticipated grants for roughly the next three years and provides stockholder oversight by requiring future increases to be approved. Key plan features strengthen stockholder protections: repricing is prohibited without stockholder approval, director compensation limits are codified (with a first-year exception), dividend equivalents on unvested awards are subject to forfeiture if awards forfeit, and share recycling rules are changed so that shares used to satisfy exercise prices or tax withholding do not return to the reserve (increasing longevity of the pool). The Company frames equity awards as vital to attracting and retaining talent after a significant October 2025 financing that materially increased outstanding common shares and diluted existing equity holders — the Board believes the larger, fixed pool addresses retention and competitive needs while improving governance. If approved, contingent grants to non-employee directors (Proposal 7) will also be granted under this amended plan; those contingent grants are conditioned on both proposals passing. For investors, the proposal balances continued equity-based alignment and retention against incremental dilution: the pool equals about 25% of outstanding shares as of the record date (or ~20% assuming exercise of prefunded warrants), a meaningful potential overhang that should be considered alongside anticipated grant pacing. Overall, the plan aligns with common market practices and contains safeguards, but investors should monitor actual grant activity and dilution metrics post-approval.

Proposal 5 requests shareholder approval for an amended ESPP that increases the share reserve to 837,000 shares and removes the plan’s prior automatic annual increases. The amended plan includes both a Section 423-qualified component (for U.S. tax-favored treatment) and a Non-423 component to allow broader participation where Section 423 requirements cannot be met. Key terms include payroll-deduction purchases (up to 15% of earnings), a purchase price equal to 85% of the lower of the offering start or purchase date fair market value, and typical eligibility and transfer restrictions; the board may exclude highly compensated employees and limit individual participation consistent with tax rules. Management frames the ESPP as an important retention and alignment tool to allow employees to share in long-term stockholder value while enhancing recruitment. The increase in reserved shares is modest relative to the EIP request but still represents potential dilution and should be evaluated in combination with other equity proposals (EIP and director grants). From a governance perspective, removal of the evergreen feature brings the ESPP under direct shareholder oversight for future increases, which investors generally view favorably. If approved, the program provides employees with a clear, market-standard benefit, but investors should track participation rates and the share usage over time to assess dilution impact.

This advisory (non-binding) proposal asks shareholders to approve the disclosed compensation of the Company’s named executive officers. The Board has adopted a policy to solicit an advisory vote every three years and believes the program emphasizes pay-for-performance and market alignment; compensation includes base salary, annual discretionary cash incentives tied to corporate and individual performance, and long-term equity awards designed for retention and alignment. While the vote is non-binding, management and the Compensation Committee state they will consider the outcome in future compensation decisions. Investors should view this as a governance signal: a strong 'For' vote supports current compensation philosophy and practices, while a low level of support would likely trigger engagement and potential plan changes. Key areas to monitor include the size and mix of equity awards (grant-date fair values), the presence of performance-based elements (including market-based PRSUs for the CEO), and change-in-control and severance protections for executives, which could affect shareholder perception of risk and pay alignment. Because the vote is non-binding, its main effect is reputational, but it can influence compensation committee actions and disclosure improvement. Overall, the proposal is standard for public companies and is a mechanism for shareholder feedback on executive pay.

Proposal 7 asks shareholders to approve large, one-time RSU awards to the three non-employee directors in specific amounts (approximately 1.5M RSUs to the chair and ~592k RSUs to each other non-employee director), to be issued under the A&R 2021 Equity Incentive Plan if that plan is approved. Management frames the grants as restorative and alignment-focused: a recent Financing in October 2025 massively increased outstanding shares and materially diluted director ownership (management cites an ~1,854.5% issuance relative to pre-financing outstanding shares), leaving non-employee directors holding negligible percentages of outstanding stock. The Contingent Grants are conditioned on both the EIP approval and this proposal; if either fails, the grants are canceled and directors would instead receive the standard 2026 annual award (~$283,000 value). The RSUs vest over three years in equal annual installments, accelerate on a change in control or death, and carry a restriction preventing sale of net shares for three years after vesting, plus subject to stock ownership guidelines—these features aim to strengthen long-term alignment and retention. From a governance/economic perspective, the grants represent significant potential dilution and concentrate value in directors; the Compensation Committee relied on external consultants and peer data but also balanced the need to restore ownership after heavy dilution. Analysts should weigh the grants’ potential benefits for director alignment and retention against dilution and optics of awarding large amounts to insiders shortly after a dilutive financing; monitoring post-grant ownership, vesting realization and whether future grants follow a normalized schedule will be important for assessing shareholder value impact.